contingent value right

(redirected from Contingent Value Rights)

Contingent Value Right

A right attached to a stock entitling the holder to the difference between the share price and some stated amount of money should the share price not exceed that amount in a given period of time. CVRs are most often attached to stocks after a merger or acquisition to encourage shareholders not to sell, and to give the new situation a chance to become profitable.

contingent value right (CVR)

The right to a cash payment if the average price of an underlying security fails to reach a specified level by a certain date. The size of the payment to the owner of the right depends on the difference between the specified and actual prices. The CVR expires without value if the actual price of the underlying security exceeds the specified price.
Mentioned in ?
References in periodicals archive ?
In addition, shareholders will receive contingent value rights entitling them to pro rata proceeds relating to deferred consideration from the sale of PDC and any proceeds from the sale of Safeway's 49% interest in Casa Ley.
The transaction also covers contingent value rights giving right to shares for an additional value of up to $55 million, based on the potential US Food and Drug Administration (FDA) approval(s) of AC-170 and two additional undisclosed products within a pre-determined period.
Additionally, the company said that since the terms for distribution of common shares to holders of its Contingent Value Rights (CVRs) were not met as of the February 8, 2010 Measurement Date, they have expired without value.
ACLARA stockholders will own around 48% of the company and have contingent value rights for potential cash payments.
Additionally, SCMF shareholders will receive non-transferable contingent value rights entitling them to receive up to $1.
On October 6, 2014, WilmerHale client Durata Therapeutics announced that it had entered into a definitive merger agreement with Actavis plc under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23 per share in cash, or approximately $675 million in the aggregate, and contingent value rights entitling the holder to receive additional cash payments of up to $5 per share if certain regulatory or commercial milestones related to Durata's lead product DALVANCE are achieved.
00 in cash for each share of Durata common stock they own, as well as contingent value rights entitling the holder to additional cash payments of up to $5.
00 in cash for each share of Durata stock they own, as well as contingent value rights entitling the holder to receive additional cash payments of up to $5.
Aciex shareholders will receive an upfront payment of $65 million entirely in the form of 20,627,024 newly issued Nicox shares, plus contingent value rights (CVRs) giving right to Nicox shares based on the potential FDA approval(s) of AC-170 and of two additional undisclosed products within a pre-determined period.
According to Nicox, the agreement comprises a $65 million upfront payment in newly issued Nicox shares and contingent value rights to shares that may raise the purchase total to a maximum of $120 million.
44 in cash per share and contingent value rights that could pay up to $1.